z-logo
open-access-imgOpen Access
Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist
Author(s) -
Hugh S. Taylor,
Linda C. Giudice,
Bruce A. Lessey,
Maurício Simões Abrão,
Jan Kotarski,
David F. Archer,
Michael P. Diamond,
Eric S. Surrey,
Neil P. Johnson,
Nelson B. Watts,
John C. Gallagher,
James A. Simon,
Bruce R. Carr,
W. Paul Dmowski,
Nicholas Leyland,
J.P. Rowan,
W. Rachel Duan,
Juki Ng,
Brittany Schwefel,
James W. Thomas,
Rita I. Jain,
Kristof Chwalisż
Publication year - 2017
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa1700089
Subject(s) - medicine , endometriosis , antagonist , hormone antagonist , gonadotropin releasing hormone , gonadotropin releasing hormone antagonist , gynecology , hormone , luteinizing hormone , receptor
Endometriosis is a chronic, estrogen-dependent condition that causes dysmenorrhea and pelvic pain. Elagolix, an oral, nonpeptide, gonadotropin-releasing hormone (GnRH) antagonist, produced partial to nearly full estrogen suppression in previous studies.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom